Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 83Breast Neoplasms 55Prostatic Neoplasms 40Lung Neoplasms 35Multiple Myeloma 34Neoplasms 26Colorectal Neoplasms 23Leukemia, Lymphocytic, Chronic, B-Cell 22Parkinson Disease 4, Autosomal Dominant Lewy Body 20Neoplasm Metastasis 20Ovarian Neoplasms 18Carcinoma, Renal Cell 16Urinary Bladder Neoplasms 13Small Cell Lung Carcinoma 13Pancreatic Neoplasms 13Myasthenia Gravis 12Leukemia, Myeloid, Acute 12Endometrial Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Nasopharyngeal Carcinoma 11Stomach Neoplasms 10Non-Muscle Invasive Bladder Neoplasms 10Recurrence 9Lymphoma, Non-Hodgkin 9Lymphoma, Follicular 9Fallopian Tube Neoplasms 9Triple Negative Breast Neoplasms 8Colonic Neoplasms 8Lymphoma, Large B-Cell, Diffuse 7Burkitt Lymphoma 7

Interventions

temsirolimus 1Vinorelbine 1Vincristine 1Sirolimus 1Radiotherapy 1Radiation 1Irinotecan 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Rhabdomyosarcoma, Alveolar × 30 days × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡